Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) has obtained a mean price target of $137.83 by market experts. The research group First Call has reached this mean recommendation by taking into account the recommendations of leading analysts in the market. These market experts have disclosed projected earnings of $0.91 a share for the near-term quarter and $3.30 for this year. Technical View The technical analysis of Ligand Pharmaceuticals Incorpor clearly shows that the moving average of 50-days of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) stock is $117.67, and stock is trading -2.47 or -2.10% off from $117.67. Coming to moving average of 200-days, it is $108.03, and the stock is $7.17 or +6.64% off from this point. The 52-week high of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) was $131.84 while $71.63 is the low in the same period. This state Ligand Pharmaceuticals Incorpor shares price has to travel more than $-16.64 to register a new high of 52-weeks or drop $+60.83% to touch a new 52-week low point. MA here stands for moving average. Taking the Valuation Aspect To reach the estimation of Ligand Pharmaceuticals Incorpor, investors use price-to-earnings ratio, which is truncated as P/E ratio. It assesses shares price by the relative expense of the stock. Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) ratio came in at 9.48, which was derived by dividing current price of stock by yearly earnings. Ligand Pharmaceuticals Incorpor stock recorded a close of $115.20 in last trading session, reaching a market cap of $2.40B. Investors calculate the Price-to-Earnings-Growth ratio to get a clear view on the valuation of a firm. In the case of a higher PEG ratio, the shareholders look to sell their stock holdings. The undervalued stock has a PEG ratio of 0 or 1 while the fairly valued stock has the ratio of 1 and 2. The Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) PEG ratio is at 0.76.
1 Chart Pattern Every Investor Should Know